Stock Analiz

Psyence Biomedical Ltd. PBM

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$3.15Market cap $17M
Open the interactive analysis →

Psyence Biomedical Ltd. (PBM) is a healthcare company listed in the US with a market value of about $17M.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).

Key numbers: a P/E of 16.5.

About Psyence Biomedical

Psyence Biomedical is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 1 of the last 3 years in our data.

Score: 1.4 / 5

Value2/5
Future growth0/5
Track record1/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)16.5
Forward P/E—
P/FCF—
P/S—
P/B2.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-22.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)—
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 3 years

Fiscal year202520242023
Revenue———
Net income$1M-$51M-$3M
Free cash flow-$4M-$3M—
EPS (diluted)$0.19$-9.62$-0.60
Net margin———
ROIC———

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Psyence Biomedical’s P/E ratio?

About 16.5, based on the last twelve months of diluted earnings per share.

Does Psyence Biomedical pay a dividend?

Not currently.

Is Psyence Biomedical a good stock to buy?

We do not give buy or sell advice. Psyence Biomedical scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.